Portal de Periódicos da CAPES

Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shock

2012; American College of Physicians; Volume: 157; Issue: 4 Linguagem: Inglês

10.7326/0003-4819-157-4-201208210-02011

1539-3704

Christian Brun‐Buisson,

Intensive Care Unit Cognitive Disorders

ACP Journal Club21 August 2012Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shockChristian Brun-Buisson, MDChristian Brun-Buisson, MDCHU Henri Mondor, AP-HP, Créteil, France (C.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-4-201208210-02011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationRanieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64. https://pubmed.ncbi.nlm.nih.gov/22616830Clinical Impact RatingsHospitalists: Infectious Disease: Critical Care: References1 Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709. [PMID: 11236773] Google Scholar2 Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369:836-43. [PMID: 17350452] Google Scholar3 Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-41. [PMID: 16192478] Google Scholar Author, Article, and Disclosure InformationAuthors: Christian Brun-Buisson, MDAffiliations: CHU Henri Mondor, AP-HP, Créteil, France (C.B.)This article was published at Annals.org on 7 August 2012. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 August 2012Volume 157, Issue 4Page: JC2-11KeywordsDrugsHemorrhageMortalityResuscitationSaline solutionsSepsisSerious adverse eventsShockVasopressorsWeaning ePublished: 21 August 2012 Issue Published: 21 August 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...